Cargando…

Lenvatinib Plus PD-1 Inhibitors versus Regorafenib in Patients with Advanced Hepatocellular Carcinoma After the Failure of Sorafenib: A Retrospective Study

PURPOSE: To evaluate the clinical outcomes of lenvatinib plus PD-1 inhibitors (LP) and regorafenib (R) in patients with advanced hepatocellular carcinoma (HCC) after sorafenib failure. METHODS: From June 2018 to September 2021, 68 patients from a single center who received lenvatinib combined with P...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Yongkang, Fu, Shumin, Liu, Kan, Mao, Ye, Wu, Jianbing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10612499/
https://www.ncbi.nlm.nih.gov/pubmed/37899984
http://dx.doi.org/10.2147/TCRM.S420371
_version_ 1785128714453909504
author Xu, Yongkang
Fu, Shumin
Liu, Kan
Mao, Ye
Wu, Jianbing
author_facet Xu, Yongkang
Fu, Shumin
Liu, Kan
Mao, Ye
Wu, Jianbing
author_sort Xu, Yongkang
collection PubMed
description PURPOSE: To evaluate the clinical outcomes of lenvatinib plus PD-1 inhibitors (LP) and regorafenib (R) in patients with advanced hepatocellular carcinoma (HCC) after sorafenib failure. METHODS: From June 2018 to September 2021, 68 patients from a single center who received lenvatinib combined with PD-1 inhibitors or regorafenib after sorafenib treatment failure were analyzed. The tumor response and survival outcomes were compared between the LP group and R group. Prognostic factors for OS and PFS were determined using Cox proportional hazard regression models. RESULTS: The ORR increased in the LP group (19.5% vs 7.4%, p =0.294), and the DCR was better in the R group (73.2% vs 44.4%, p =0.017). Additionally, median PFS and OS were not significantly different between the LP group and R two groups in survival analysis (PFS: 5.3 months vs 3.0 months, p =0.633; OS: 11.8 months vs 8.0 months, p =0.699). The common adverse events (≥grade 3) were hand-foot skin reactions (13.1%). In multivariate analyses, AFP≥400 ng/mL and ECOG PS 2 were independent risk factors for poor prognosis. CONCLUSION: The LP group appeared to have a trend of greater tumor response and a higher disease control rate than the R group among patients with sorafenib-resistant HCC, although PFS and OS did not differ significantly between the two groups.
format Online
Article
Text
id pubmed-10612499
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-106124992023-10-29 Lenvatinib Plus PD-1 Inhibitors versus Regorafenib in Patients with Advanced Hepatocellular Carcinoma After the Failure of Sorafenib: A Retrospective Study Xu, Yongkang Fu, Shumin Liu, Kan Mao, Ye Wu, Jianbing Ther Clin Risk Manag Original Research PURPOSE: To evaluate the clinical outcomes of lenvatinib plus PD-1 inhibitors (LP) and regorafenib (R) in patients with advanced hepatocellular carcinoma (HCC) after sorafenib failure. METHODS: From June 2018 to September 2021, 68 patients from a single center who received lenvatinib combined with PD-1 inhibitors or regorafenib after sorafenib treatment failure were analyzed. The tumor response and survival outcomes were compared between the LP group and R group. Prognostic factors for OS and PFS were determined using Cox proportional hazard regression models. RESULTS: The ORR increased in the LP group (19.5% vs 7.4%, p =0.294), and the DCR was better in the R group (73.2% vs 44.4%, p =0.017). Additionally, median PFS and OS were not significantly different between the LP group and R two groups in survival analysis (PFS: 5.3 months vs 3.0 months, p =0.633; OS: 11.8 months vs 8.0 months, p =0.699). The common adverse events (≥grade 3) were hand-foot skin reactions (13.1%). In multivariate analyses, AFP≥400 ng/mL and ECOG PS 2 were independent risk factors for poor prognosis. CONCLUSION: The LP group appeared to have a trend of greater tumor response and a higher disease control rate than the R group among patients with sorafenib-resistant HCC, although PFS and OS did not differ significantly between the two groups. Dove 2023-10-24 /pmc/articles/PMC10612499/ /pubmed/37899984 http://dx.doi.org/10.2147/TCRM.S420371 Text en © 2023 Xu et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Xu, Yongkang
Fu, Shumin
Liu, Kan
Mao, Ye
Wu, Jianbing
Lenvatinib Plus PD-1 Inhibitors versus Regorafenib in Patients with Advanced Hepatocellular Carcinoma After the Failure of Sorafenib: A Retrospective Study
title Lenvatinib Plus PD-1 Inhibitors versus Regorafenib in Patients with Advanced Hepatocellular Carcinoma After the Failure of Sorafenib: A Retrospective Study
title_full Lenvatinib Plus PD-1 Inhibitors versus Regorafenib in Patients with Advanced Hepatocellular Carcinoma After the Failure of Sorafenib: A Retrospective Study
title_fullStr Lenvatinib Plus PD-1 Inhibitors versus Regorafenib in Patients with Advanced Hepatocellular Carcinoma After the Failure of Sorafenib: A Retrospective Study
title_full_unstemmed Lenvatinib Plus PD-1 Inhibitors versus Regorafenib in Patients with Advanced Hepatocellular Carcinoma After the Failure of Sorafenib: A Retrospective Study
title_short Lenvatinib Plus PD-1 Inhibitors versus Regorafenib in Patients with Advanced Hepatocellular Carcinoma After the Failure of Sorafenib: A Retrospective Study
title_sort lenvatinib plus pd-1 inhibitors versus regorafenib in patients with advanced hepatocellular carcinoma after the failure of sorafenib: a retrospective study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10612499/
https://www.ncbi.nlm.nih.gov/pubmed/37899984
http://dx.doi.org/10.2147/TCRM.S420371
work_keys_str_mv AT xuyongkang lenvatinibpluspd1inhibitorsversusregorafenibinpatientswithadvancedhepatocellularcarcinomaafterthefailureofsorafenibaretrospectivestudy
AT fushumin lenvatinibpluspd1inhibitorsversusregorafenibinpatientswithadvancedhepatocellularcarcinomaafterthefailureofsorafenibaretrospectivestudy
AT liukan lenvatinibpluspd1inhibitorsversusregorafenibinpatientswithadvancedhepatocellularcarcinomaafterthefailureofsorafenibaretrospectivestudy
AT maoye lenvatinibpluspd1inhibitorsversusregorafenibinpatientswithadvancedhepatocellularcarcinomaafterthefailureofsorafenibaretrospectivestudy
AT wujianbing lenvatinibpluspd1inhibitorsversusregorafenibinpatientswithadvancedhepatocellularcarcinomaafterthefailureofsorafenibaretrospectivestudy